Marks’ exit at FDA rattles an already teetering biotech industry

Drew Armstrong

Executive Editor

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

The departure of one of the FDA’s highest-profile regulators, whose career was defined by advancing new technologies to patients, rattled investors and companies who were …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Marks’ exit at FDA rattles an already teetering biotech industry

Drew Armstrong

Executive Editor

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Sanofi continues its bet on R&D by poaching GSK’s head of development

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Executive Editor

Senior Editor

Senior Reporter

Sign up to read this article for free.

Marks’ exit at FDA rattles an already teetering biotech industry